Fig 6.

SN50 treatment reduced axonal outgrowth. Mock- and CVS-infected cultures for 72 h (n = 19 to 62) were treated or not treated with SN50 for 72 h. Evaluation of axonal outgrowth by determining the length of total axon outgrowth per neuron shows that, in comparison to mock-infected cells without SN50 (164.2 ± 7.3), SN50 significantly reduced axonal outgrowth in CVS-infected neurons (113.4 ± 7.4; ***, P < 0.0001). Without SN50, CVS-infected neurons significantly reduced outgrowth of their axons at 72 h p.i. (105.6 ± 7.3) compared to that of mock-infected neurons (***, P < 0.0001). There was a greater inhibition of outgrowth with the combination of SN50 and CVS infection (53.0 ± 5.1) than with either CVS infection without SN50 (**, P < 0.001) or mock infection with SN50 (**, P < 0.001). There was no significant difference in axonal outgrowth between mock infection treated without SN50 versus with SN50M (P = 0.12).